51 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? https://www.fool.com/investing/2019/09/05/is-the-fda-out-to-get-this-29-billion-diabetes-dru.aspx?source=iedfolrf0000001 Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease http://www.zacks.com/stock/news/503280/endo-gains-fda-nod-for-orfadin-generic-to-treat-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503280 Sep 05, 2019 - Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503575 Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Buy 5 Top Dow Stocks to Gain From Index's Rally http://www.zacks.com/stock/news/510834/buy-5-top-dow-stocks-to-gain-from-indexs-rally?cid=CS-ZC-FT-analyst_blog|investment_ideas-510834 Sep 10, 2019 - The Dow is expected to maintain its current momentum for the rest of this month and further due to two immediate catalysts.
4 Big Drugmakers Boasting Impressive Oncology Pipelines http://www.zacks.com/stock/news/513001/4-big-drugmakers-boasting-impressive-oncology-pipelines?cid=CS-ZC-FT-analyst_blog|industry_focus-513001 Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study http://www.zacks.com/stock/news/517413/roches-new-perjeta-combo-meets-goal-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-517413 Sep 13, 2019 - Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis http://www.zacks.com/stock/news/522810/jj-files-sbla-for-tremfya-with-fda-for-psoriatic-arthritis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-522810 Sep 17, 2019 - J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids http://www.zacks.com/stock/news/532006/glaxos-benlysta-gets-positive-chmp-opinion-for-use-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-532006 Sep 23, 2019 - Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
Company News for Sep 23, 2019 http://www.zacks.com/stock/news/531869/company-news-for-sep-23-2019?cid=CS-ZC--corporate_summary-531869 Sep 23, 2019 - Companies In The News Are: MDR, MRK, NFLX, XLNX
Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose http://www.zacks.com/stock/news/535522/bristol-myers-opdivo-gains-positive-chmp-view-for-new-dose?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-535522 Sep 25, 2019 - Bristol-Myers (BMY) receives a positive response from the CHMP for a four-week dosing option with Opdivo as an adjuvant treatment of adult patients with melanoma.

Pages: 123456

Page 1>